Investigational therapies for squamous cell lung cancer

from animal studies to phase II trials

Elaine Shum, Feng Wang, Salem Kim, Roman Perez-Soler, Haiying Cheng

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: It remains challenging to treat squamous cell lung cancer (SCC) with limited therapeutic options. However, recent breakthroughs in targeted therapies and immunotherapies have shed some light on the management of this deadly disease. Areas covered: The article first reviews the current treatment options for advanced SCC, especially recent FDA approved molecular agents (afatinib, ramucirumab and necitumumab) and immunotherapies (nivolumab, pembrolizumab and atezolimumab). We then provide an overview on investigational therapies with data ranging from preclinical to phase II studies, focusing on new cytotoxic agents, emerging molecularly targeted agents (including a PARP inhibitor for Homologous Recombinant Deficiency positive SCC) and novel immunotherapeutic strategies. Expert opinion summary: Identification of potential therapeutic targets, development of novel clinical trials and the rapid approvals of immune checkpoint inhibitors have shifted the management paradigm for squamous cell lung cancer. On the other hand, continued efforts are needed to identify the predictive biomarkers and to investigate novel mechanistically-driven mono- and combination therapies. We need to learn more about the biology behind immune checkpoint blockade and tumor genomics in SCC for better patient selection and future trial design.

Original languageEnglish (US)
Pages (from-to)415-426
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Squamous Cell Neoplasms
Investigational Therapies
Lung Neoplasms
Immunotherapy
Therapeutics
Cytotoxins
Expert Testimony
Disease Management
Genomics
Patient Selection
Biomarkers
Clinical Trials
Neoplasms

Keywords

  • immunotherapy
  • novel therapy
  • Squamous cell lung cancer
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational therapies for squamous cell lung cancer : from animal studies to phase II trials. / Shum, Elaine; Wang, Feng; Kim, Salem; Perez-Soler, Roman; Cheng, Haiying.

In: Expert Opinion on Investigational Drugs, Vol. 26, No. 4, 03.04.2017, p. 415-426.

Research output: Contribution to journalReview article

@article{7472755c1d974f2383bc7d59748d3508,
title = "Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials",
abstract = "Introduction: It remains challenging to treat squamous cell lung cancer (SCC) with limited therapeutic options. However, recent breakthroughs in targeted therapies and immunotherapies have shed some light on the management of this deadly disease. Areas covered: The article first reviews the current treatment options for advanced SCC, especially recent FDA approved molecular agents (afatinib, ramucirumab and necitumumab) and immunotherapies (nivolumab, pembrolizumab and atezolimumab). We then provide an overview on investigational therapies with data ranging from preclinical to phase II studies, focusing on new cytotoxic agents, emerging molecularly targeted agents (including a PARP inhibitor for Homologous Recombinant Deficiency positive SCC) and novel immunotherapeutic strategies. Expert opinion summary: Identification of potential therapeutic targets, development of novel clinical trials and the rapid approvals of immune checkpoint inhibitors have shifted the management paradigm for squamous cell lung cancer. On the other hand, continued efforts are needed to identify the predictive biomarkers and to investigate novel mechanistically-driven mono- and combination therapies. We need to learn more about the biology behind immune checkpoint blockade and tumor genomics in SCC for better patient selection and future trial design.",
keywords = "immunotherapy, novel therapy, Squamous cell lung cancer, targeted therapy",
author = "Elaine Shum and Feng Wang and Salem Kim and Roman Perez-Soler and Haiying Cheng",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/13543784.2017.1302425",
language = "English (US)",
volume = "26",
pages = "415--426",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Investigational therapies for squamous cell lung cancer

T2 - from animal studies to phase II trials

AU - Shum, Elaine

AU - Wang, Feng

AU - Kim, Salem

AU - Perez-Soler, Roman

AU - Cheng, Haiying

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: It remains challenging to treat squamous cell lung cancer (SCC) with limited therapeutic options. However, recent breakthroughs in targeted therapies and immunotherapies have shed some light on the management of this deadly disease. Areas covered: The article first reviews the current treatment options for advanced SCC, especially recent FDA approved molecular agents (afatinib, ramucirumab and necitumumab) and immunotherapies (nivolumab, pembrolizumab and atezolimumab). We then provide an overview on investigational therapies with data ranging from preclinical to phase II studies, focusing on new cytotoxic agents, emerging molecularly targeted agents (including a PARP inhibitor for Homologous Recombinant Deficiency positive SCC) and novel immunotherapeutic strategies. Expert opinion summary: Identification of potential therapeutic targets, development of novel clinical trials and the rapid approvals of immune checkpoint inhibitors have shifted the management paradigm for squamous cell lung cancer. On the other hand, continued efforts are needed to identify the predictive biomarkers and to investigate novel mechanistically-driven mono- and combination therapies. We need to learn more about the biology behind immune checkpoint blockade and tumor genomics in SCC for better patient selection and future trial design.

AB - Introduction: It remains challenging to treat squamous cell lung cancer (SCC) with limited therapeutic options. However, recent breakthroughs in targeted therapies and immunotherapies have shed some light on the management of this deadly disease. Areas covered: The article first reviews the current treatment options for advanced SCC, especially recent FDA approved molecular agents (afatinib, ramucirumab and necitumumab) and immunotherapies (nivolumab, pembrolizumab and atezolimumab). We then provide an overview on investigational therapies with data ranging from preclinical to phase II studies, focusing on new cytotoxic agents, emerging molecularly targeted agents (including a PARP inhibitor for Homologous Recombinant Deficiency positive SCC) and novel immunotherapeutic strategies. Expert opinion summary: Identification of potential therapeutic targets, development of novel clinical trials and the rapid approvals of immune checkpoint inhibitors have shifted the management paradigm for squamous cell lung cancer. On the other hand, continued efforts are needed to identify the predictive biomarkers and to investigate novel mechanistically-driven mono- and combination therapies. We need to learn more about the biology behind immune checkpoint blockade and tumor genomics in SCC for better patient selection and future trial design.

KW - immunotherapy

KW - novel therapy

KW - Squamous cell lung cancer

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85016158506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016158506&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1302425

DO - 10.1080/13543784.2017.1302425

M3 - Review article

VL - 26

SP - 415

EP - 426

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -